Clinical Trial Update: ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating ACY-1215 (ricolinostat) in combination with B-cell receptor pathway inhibitors for relapsed chronic lymphocytic leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ricolinostat (ACY-1215) (ricolinostat)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Recurrent Chronic Lymphoid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING